[Oxaliplatin: combinations with thymidylate synthetase inhibitors: two consecutive phase II studies].
Martoni
A
A
UO di Oncologia Medica, Dipartimento di Oncologia e Ematologia, Policlinico Sant'Orsola-Malpighi, Bologna.
Mini
E
E
Pinto
C
C
Gentile
A
A
Mazzei
T
T
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011799:Quinazolines / Q000008:administration & dosage; D013876:Thiophenes / Q000008:administration & dosage; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D009944:Organoplatinum Compounds; D011799:Quinazolines; D013876:Thiophenes; D000077150:Oxaliplatin; D013940:Thymidylate Synthase; C068874:raltitrexed; D005472:Fluorouracil